Curated News
By: NewsRamp Editorial Staff
November 13, 2026
Oragenics Wins NYSE Extension to 2028, Aims to Regain Compliance
TLDR
- Oragenics gains a NYSE listing extension to Feb. 25, 2028, buying time to raise capital and advance ONP-002 ahead of rivals.
- Oragenics must meet NYSE American plan milestones and review requirements after its $3.7 million equity shortfall triggered noncompliance in August 2026.
- Oragenics' intranasal ONP-002 could bring first-in-class concussion treatment to patients with significant unmet neurological needs.
- Oragenics' intranasal platform may extend beyond concussion to Parkinson's, Alzheimer's, PTSD, and anxiety disorders.
Impact - Why it Matters
This news matters because it provides Oragenics with a crucial runway to address its financial challenges without the immediate threat of delisting, allowing the company to focus on advancing its promising intranasal treatment for concussion and other neurological conditions. For investors, the extension reduces near-term risk and signals regulatory flexibility, while for patients, it keeps hope alive for a potential first-in-class therapy that could address significant unmet needs in brain injury and neurodegenerative diseases. The outcome will depend on Oragenics' ability to execute its compliance plan and deliver on its clinical milestones.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biopharmaceutical company focused on neurological therapeutics, has received approval from NYSE Regulation for its compliance plan, granting an extension until February 25, 2028, to regain compliance with NYSE American continued listing standards. The approval enables Oragenics to maintain its exchange listing while implementing measures to strengthen its financial position, provided it meets plan milestones and ongoing review requirements. The company had received a noncompliance notice on August 26, 2026, after reporting stockholders’ equity of $3.7 million as of June 30, 2026, and losses from continuing operations and/or net losses in its five most recent fiscal years.
Oragenics submitted its compliance plan on September 25, 2026, and received formal acceptance on November 11. CEO Janet Huffman stated that the extension will allow Oragenics to continue pursuing its strategic priorities, capital-raising initiatives, and investment strategies aimed at enhancing long-term shareholder value. The company is developing brain-targeted therapeutics through proprietary intranasal delivery technology, with its lead candidate ONP-002 as a potential first-in-class treatment for concussion and mild traumatic brain injury. Oragenics is working on commencing clinical trials in Australia for ONP-002, with U.S. Phase 2b trials planned to follow. Its intranasal delivery platform has potential applications across multiple neurological conditions, including Parkinson’s disease, Alzheimer’s disease, PTSD, and anxiety disorders. For more information, visit oragenics.com. The latest news and updates relating to OGEN are available in the company’s newsroom at https://ibn.fm/OGEN. The announcement was distributed through BioMedWire, a specialized communications platform for the biotech and life sciences sectors.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Wins NYSE Extension to 2028, Aims to Regain Compliance
